Breast Cancer Survivors, Mindfulness Based Cognitive Therapy, Oncology, Quality of Life, Symptom Management
Conditions
Brief summary
Breast cancer is the most common cancer in women in Singapore. Breast cancer survivors usually experience side effects/symptoms after surgery and/or adjuvant chemotherapy and/or radiotherapy such as fatigue, lymphedema, problems with sleeping, peripheral neuropathy, and anxiety/depression. Currently, there is no study to include both symptom management and mindfulness training components for breast cancer survivors. And given breast cancer survivors have infrequent clinical follow-up, we aim to develop an e-Home based symptom management and mindfulness training programme for breast cancer survivors and to determine its effects on quality of life, symptom distress, psychosocial adjustment, psychological morbidity, and unplanned outpatient attendance or hospitalisation in breast cancer survivors. We employ a randomised clinical trial with four study arms (with 47 subjects in each arm) together with a process evaluation; group 1 (usual care), group 2 (experimental group: five weekly sessions of online symptom management + mindfulness training programme and usual care), group 3 (comparison group 1: five weekly sessions of online symptom management programme and usual care), and group 4 (comparison group 2: five weekly sessions of online mindfulness training programme and usual care). Subjects will complete questionnaires measures of 6-item Social Support Questionnaire, Breast Cancer Survivor Self-Efficacy Scale, the Quality of Life-Cancer Survivor Scale, Memorial Symptom Assessment Scale, Psychosocial Adjustment to Illness Scale, short version of the Fear of Recurrence Scale, Hospital and anxiety Depression Scale and Five Facet Mindfulness Questionnaire at baseline (printed questionnaires), at 8 weeks from baseline, at 12 weeks from baseline and at 24 weeks from baseline by an online system or printed questionnaires. Individualised semi-structured interview (15-25 mins) for experimental and comparison groups will be conducted at 24 weeks from baseline to understand the subjects' experiences of the study programme. Data will be analysed using SPSS version 24. Baseline demographic and clinical information of subjects in the experimental, comparison and control groups will be summarised using descriptive statistics, and will be compared using chi square tests and ANOVA/ANCOVA tests. Intention-to-treat approach will be used. Repeated measures analysis of variance will be used to examine the differences on outcome measures among the experimental, comparison and control groups across study time points. In addition, differences in changes in outcome measures among experimental, comparison groups and usual care groups will be tested using multilevel modelling techniques. A p-value smaller than 5% will be considered as statistically significant. Content analysis will be conducted to analyse the interviews data.
Interventions
5 weekly sessions of online self-administered mindfulness training programme in which they will receive audio-recorded and video-recorded instructions, pictorial or text-based instructions for various mindfulness exercises such as body scan meditation, mindful breathing and walking meditation.
OTHEROnline symptom management
5 weekly online education module in which they will receive video-recorded, audio-recorded, pictorial or text-based instructions for various self-management strategies. Topics include fatigue, pain, numbness/tingling, lymphedema, anxiety/depression, and problems with sleeping.
Sponsors
National University Hospital, Singapore
National Cancer Centre, Singapore
National University of Singapore
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
21 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* women aged 21 or above * able to speak and read English * diagnosed with breast cancer stage 0 to 3 for the first time * have completed cancer treatment including breast surgery and/or adjuvant chemotherapy and/or radiotherapy between 6 months to 5 years previously * with and without ongoing HER2 target therapy (e.g.: Herceptin) and/or hormonal therapy * with ECOG Performance Status score of 0 to 1 * able to understand the study and give informed consent * have access to the internet through a handheld device
Exclusion criteria
* they are illiterate * have serious psychiatric disorders (e.g. schizophrenia, dementia, and intellectual disabilities) * with ECOG Performance Status score of 2 or above
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline quality of life score at 8 weeks | Change between baseline and at 8 weeks |
| Change from baseline quality of life score at 12 weeks | Change between baseline and at 12 weeks |
| Change from baseline quality of life score at 24 weeks | Change between baseline and at 24 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline self-efficacy score at 8 weeks | Change between baseline and at 8 weeks |
| Change from baseline self-efficacy score at 12 weeks | Change between baseline and at 12 weeks |
| Change from baseline self-efficacy score at 24 weeks | Change between baseline and at 24 weeks |
| Change from baseline symptom score at 8 weeks | Change between baseline and at 8 weeks |
| Change from baseline symptom score at 12 weeks | Change between baseline and at 12 weeks |
| Change from baseline symptom score at 24 weeks | Change between baseline and at 24 weeks |
| Change from baseline psychosocial adjustment to illness score at 8 weeks | Change between baseline and at 8 weeks |
| Change from baseline psychosocial adjustment to illness score at 12 weeks | Change between baseline and at 12 weeks |
| Change from baseline psychosocial adjustment to illness score at 24 weeks | Change between baseline and at 24 weeks |
| Change from baseline social support score at 8 weeks | Change between baseline and at 8 weeks |
| Change from baseline fear of recurrence score at 12 weeks | Change between baseline and at 12 weeks |
| Change from baseline fear of recurrence score at 24 weeks | Change between baseline and at 24 weeks |
| Change from baseline anxiety and depression score at 8 weeks | Change between baseline and at 8 weeks |
| Change from baseline anxiety and depression score at 12 weeks | Change between baseline and at 12 weeks |
| Change from baseline anxiety and depression score at 24 weeks | Change between baseline and at 24 weeks |
| Change from baseline mindfulness score at 8 weeks | Change between baseline and at 8 weeks |
| Change from baseline mindfulness score at 12 weeks | Change between baseline and at 12 weeks |
| Change from baseline mindfulness score at 24 weeks | Change between baseline and at 24 weeks |
| Change from baseline fear of recurrence score at 8 weeks | Change between baseline and at 8 weeks |
| Change from baseline social support score at 12 weeks | Change between baseline and at 12 weeks |
| Change from baseline social support score at 24 weeks | Change between baseline and at 24 weeks |
Countries
Singapore
Outcome results
None listed